| PFE |
Report |
Q2 2026 total revenue |
BEAT |
pred ~$14.55B vs. cons $14.40B |
MEDIUM |
| PFE |
Report |
Q2 2026 adjusted diluted EPS |
BEAT |
pred ~$0.70 vs. cons $0.68 |
MEDIUM |
| PFE |
Report |
Q2 2026 Padcev revenue |
BEAT |
pred ~$650M vs. cons $640M |
LOW |
| PFE |
Guide |
FY2026 total revenue guidance |
UNCHANGED |
guide ~$61.0B midpoint vs. cons $61.0B (FY2026) |
HIGH |
| PFE |
Guide |
FY2026 adjusted diluted EPS guidance |
UNCHANGED |
guide ~$2.90 midpoint vs. cons $2.92 (FY2026) |
MEDIUM |
| PFE |
Return |
Day-1 residual (stock − beta × S&P 500) |
+1.5% |
— |
MEDIUM |
| PFE |
Return |
5-day cumulative residual |
+0.5% (STABILIZE) |
A modest ~$0.02 EPS beat versus $0.68 consensus and ~$0.15B revenue beat versus $14.40B should support an initial positive reaction, but unchanged FY2026 EPS guidance of ~$2.90 versus $2.92 consensus leaves no out-period estimate-raise catalyst; recurring-growth validation offsets but does not eliminate pricing, COVID-seasonality, and LOE concerns. |
MEDIUM |